EU approves label update for AZ’ Lokelma
Update provides dosing regimen specifically for hyperkalaemia in patients with end-stage renal disease on stable haemodialysis
Read More
Tag: hyperkalaemia
US clears label update for AZ’ Lokelma
The drug’s label now includes a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable hemodialysis
Read More
NICE u-turn backs NHS use of Veltassa
The drug will be funded on the NHS to treat hyperkalaemia
Read More
NICE turns down hyperkalaemia therapies
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Read More
US green light for AZ’ Lokelma
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia – elevated potassium levels in the blood – in adult patients.
Read More
EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
Read More
EU nod for Vifor’s Veltassa
European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.
Read More
Second US rejection for AZ’ potassium binder
AstraZeneca’s hyperkalaemia treatment ZS-9 has suffered another setback on the path to US approval having been rejected by regulators for the second time. The drug giant also unveiled a US-based partnership with Circassia for development and commercialisation of COPD drugs Turdoza and Duaklir.
Read More
FDA accepts resubmission of AZ’ potassium-binder
US regulators have accepted AstraZeneca unit ZS Pharma’s resubmission of ZS-9, a potassium-binding compound being developed for hyperkalaemia.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
